Generex Biotechnology Corporation, a company engaged in the research, development, and commercialization of drug delivery systems and technologies,  has entered into a collaboration with University Health Network (UHN) pursuant to which UHN's Centre for Molecular Design and Preformulations (CMDP) will spearhead the company's buccal insulin refinement project.

The goal of the project is to increase the insulin bioavailability of Generex Oral-lyn, the company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes.  This research will ensure the product is more attractive to patients and prospective commercialization partners.

UHN, one of Canada's largest teaching hospitals, is comprised of Princess Margaret Cancer Centre, Toronto General Hospital, Toronto Rehabilitation Institute, and Toronto Western Hospital.  The UHN's CMDP, located in the Toronto Medical Discoveries Tower of the MaRS center at UHN Research in Toronto, will devote to the project its world-class chemists and molecular design scientists and its fully-equipped state-of-the-art medicinal synthetic chemistry and preformulation laboratories.

"We are most enthusiastic about the participation of University Health Network in our buccal insulin refinement project," commented Dr. James H. Anderson, Jr., the Company's Senior Scientific Advisor.  "Numerous clinical studies have established the non-inferiority of Generex Oral-lyn as a prandial insulin therapy for patients with diabetes as compared to subcutaneous injection.  Access to UHN's experienced and talented research professionals and facilities in Toronto, birthplace of the discovery of insulin, will drive our efforts to refine the product and set the stage for commercialization."

Generex Oral-lyn is designed to be a safe, simple, fast, flexible, and effective alternative to prandial insulin injections.